VALENTINE'S DAY in San Diego this year dawned cold and grim for Saundra Pelletier. It should have been a day of celebration-or at least marketing synergy-for the CEO of Evofem Biosciences, a women's health company with an unapologetically sex-positive mission. Its first and only product is a contraceptive gel called Phexxi, which Evofem markets to the millions of women eager for a birth control option without hormones. More than 100,000 people have gotten a prescription for Phexxi since it launched in late 2020; millions more have watched its $30 million viral commercial, starring Schitt's Creek comedian Annie Murphy.
But the past few years have stretched Pelletier's company to its limits. Evofem more than tripled its sales last year, to $16.7 million in the first nine months of 2022-but it lost $68.4 million over that same period and is carrying $84 million of debt. A crucial clinical trial failed in October, dooming Pelletier's efforts to expand Phexxi's market. Now some patients are casting doubt on Phexxi's basic effectiveness, claiming in online reviews that they have gotten pregnant while using the gel.
Some of these problems are of Evofem's own making. But the worst body blows-to Evofem, and to the other companies trying to serve the 47 million U.S. women who use contraception-have come from the broken health care system. Investors and large pharma companies have largely abandoned the women's health field, leaving the development of new contraceptives to small, scrappy specialists like Evofem, Agile Therapeutics, and TherapeuticsMD. But companies that have won approval for their products have quickly discovered that most big insurance companies would not pay for them, despite a federal law requiring them to do so.
This story is from the April - May 2023 edition of Fortune US.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the April - May 2023 edition of Fortune US.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
What Even I/s Luxury?
After two decades of covering food, travel, and the finer things in life, a writer still sometimes wonders, \"Am I doing this right?\"
HOT MESS
Huy Fong sriracha rose from nowhere to become an iconic American food brand. Here's how a feud between partners knocked it off its throne.
BIG PHARMA'S MONKEY BUSINESS
A CRACKDOWN ON MACAQUE SMUGGLING HAS DISRUPTED A VITAL DRUG DEVELOPMENT SUPPLY CHAIN. INSIDE THE HIGHSTAKES BATTLE OVER THE FUTURE OF AMERICAN MEDICAL INNOVATION, AND THE PRIMATE SPECIES IT DEPENDS UPON.
THE CHINA DILEMMA
For decades, American companies came to China to tap into a vast opportunity. As geopolitical tensions rise, it's getting much harder to stay-and it's just as hard to leave.
FACE TO FACE WITH FAILURE
ECONOMIC TURMOIL POSES A DAUNTING CHALLENGE TO FOUNDERS: BALANCING THEIR STARTUPS' FUTURE WITH THEIR OWN MENTAL HEALTH.
ROAD KILL
BIRD'S ELECTRIC SCOOTER BUSINESS HAD ALL THE MAKINGS OF THE NEXT
RUNNING OUT OF OXYGEN
VENTURECAPITAL-FUNDED PRIVATE MARKETS FUELED THE CREATION OF HUNDREDS OF BILLION-DOLLAR STARTUPS OVER THE PAST DECADE. NOW THOSE MARKETS ARE IN UPHEAVALAND THE UNICORNS ARE IN CRISIS.
5 Steady-Rising Stocks for 2024
Cast aside in the surge of enthusiasm for all things tech, these five non-tech options are arguably poised for big years ahead.
The Unexpected Upside of an Aging Workforce
Hiring and retaining older workers can help boost your company's bottom line.
Al's Battle Shifts to the Corridors of Power
Tech companies are sparring with regulators over how they can use and develop artificial intelligence.